CDSCO Examines Risks of Brand Name Extensions Across Different Drug Formulations
CDSCO has invited stakeholder feedback on drug brand name extensions amid concerns over therapeutic confusion and patient safety, with comments due by 17 July 2026.
Pharmaceutical Companies
CCI | Companies not to indulge in mandating clearance/NOC/LOC that are anti-competitive as per S. 3 of Competition Act
Competition Commission of India (CCI): Ashok Kumar Gupta (Chairperson) and U.C. Nahta and Sangeeta Verma (Members) heard the information filed by MPCDF